Entera Bio Ltd.
Every calculator, already run for ENTX
Open the full toolkit →You have the numbers on ENTX. Get the argument.
A written report on which of these readings actually decide the outcome for Entera Bio Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering ENTXAnalyst Price Target Disagreement for Entera Bio Ltd.
Wall Street's bull case implies +277% from the current price; the bear case implies +208%. A 68% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ENTX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Entera Bio Ltd.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial…
ENTX — frequently asked
Is ENTX a buy right now?
Wall Street's consensus rating on Entera Bio Ltd. is Strong Buy across 5 analysts, with a mean price target of $9.75 (+234% vs. the current $2.92). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ENTX's next earnings date?
Entera Bio Ltd. is next scheduled to report earnings around Nov 13, 2026. A full ENTX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Entera Bio Ltd.?
Analysts covering Entera Bio Ltd. (ENTX) range from a bear-case target of $9.00 to a bull-case high of $11.00, with a mean consensus target of $9.75 across 4 analysts. The spread of $2.00 (68% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Entera Bio Ltd. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Entera Bio Ltd.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ENTX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Entera Bio Ltd., in minutes. 3 free reports included with every account — no credit card required.